Illumina sued by shareholders for Roche rebuff
This article was originally published in Clinica
Executive Summary
Illumina is facing a putative class action filed by disgruntled shareholders accusing the company of rejecting Roche's $5.7bn takeover bid based on bad advice from investment bank Goldman Sachs.